Menactra®

BIOLOGICAL4 trials

Sponsors

GlaxoSmithKline, Sanofi Pasteur, a Sanofi Company, PATH

Conditions

Infections, MeningococcalMeningitisMeningococcal InfectionsMeningococcal Vaccines

Phase 1

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

CompletedNCT02810340

PATHMeningococcal Vaccines

Start: 2016-08-01End: 2017-10-13Updated: 2021-06-09

Phase 2

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

CompletedNCT00454909

GlaxoSmithKlineInfections, Meningococcal

Start: 2007-04-23End: 2008-04-11Updated: 2018-06-08

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults

CompletedNCT01165242

GlaxoSmithKlineInfections, Meningococcal

Start: 2010-08-19End: 2011-07-29Updated: 2018-06-26

Unknown Phase

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

CompletedNCT00862277

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infections

Start: 2008-12-31End: 2009-12-31Updated: 2016-04-14

Related Papers

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.

2018-08-1457 citations

Five-year Antibody Persistence and Booster Response to a Single Dose of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Adolescents and Young Adults: An Open, Randomized Trial.

2015-11-0125 citations

Comparison of the Safety and Immunogenicity of a Novel Quadrivalent Meningococcal ACWY-Tetanus Toxoid Conjugate Vaccine and a Marketed Quadrivalent Meningococcal ACWY-Diphtheria Toxoid Conjugate Vaccine in Healthy Individuals 10-25 Years of Age

Journal of the Pediatric Infectious Diseases Society2013-10-1728 citations